Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Urinary Tract Infections 1 Urinary Bladder Neoplasms 1 Surgical Wound Infection 1 Skin Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Inflammation 1 Infections 1 Head and Neck Neoplasms 1 Exanthema 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Carboplatin 340 Cisplatin 238 Paclitaxel 203 Radiotherapy 195 Pemetrexed 187 Docetaxel 169 Gemcitabine 157 pembrolizumab 141 Erlotinib Hydrochloride 107 Etoposide 99 Magnetic Resonance Spectroscopy 93 Bevacizumab 91 Specimen Handling 76 Nivolumab 73 Radiosurgery 72 durvalumab 69 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 49 atezolizumab 42 Irinotecan 42 Radiation 40 Topotecan 39 Biopsy 39 Standard of Care 38 Cyclophosphamide 38 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Clindamycin × Clear all

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡